{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:51:09Z","timestamp":1794865869150,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"DOI":"10.1038\/s44298-026-00201-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:05:43Z","timestamp":1780686343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Andes hantavirus \u2013 A primer"],"prefix":"10.1038","volume":"4","author":[{"given":"Nico Joel","family":"Halwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tscherne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"201_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrmicro3066","volume":"11","author":"A Vaheri","year":"2013","unstructured":"Vaheri, A. et al. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol. 11, 539\u2013550 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"201_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41586-018-0702-1","volume":"563","author":"RK Jangra","year":"2018","unstructured":"Jangra, R. K. et al. Protocadherin-1 is essential for cell entry by New World hantaviruses. Nature 563, 559\u2013563 (2018).","journal-title":"Nature"},{"key":"201_CR3","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1016\/j.cell.2026.01.030","volume":"189","author":"L Guo","year":"2026","unstructured":"Guo, L. et al. High-resolution in situ structures of hantavirus glycoprotein tetramers. Cell 189, 2731\u20132747.e15 (2026).","journal-title":"Cell"},{"key":"201_CR4","unstructured":"Oligoryzomys longicaudatus Abstract; https:\/\/www.iucnredlist.org\/species\/15250\/115126914#assessment-information."},{"key":"201_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3201\/eid2305.161770","volume":"23","author":"A de St Maurice","year":"2017","unstructured":"de St Maurice, A. et al. Exposure characteristics of Hantavirus Pulmonary Syndrome Patients, United States, 1993\u20132015. Emerg. Infect. Dis. 23, 733\u2013739 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"201_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/jmv.25446","volume":"91","author":"DO Alonso","year":"2019","unstructured":"Alonso, D. O. et al. Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary Syndrome: 9 years of surveillance in Argentina. J. Med. Virol. 91, 1173\u20131181 (2019).","journal-title":"J. Med. Virol."},{"key":"201_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1473-3099(24)00142-7","volume":"24","author":"M Ferr\u00e9s","year":"2024","unstructured":"Ferr\u00e9s, M. et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect. Dis. 24, 775\u2013782 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"201_CR8","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3201\/eid1911.130421","volume":"19","author":"H Zelen\u00e1","year":"2013","unstructured":"Zelen\u00e1, H., Mr\u00e1zek, J. & Kuhn, T. Tula hantavirus infection in immunocompromised host, Czech Republic. Emerg. Infect. Dis. 19, 1873\u20131875 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"201_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/microorganisms11020283","volume":"11","author":"P Steininger","year":"2023","unstructured":"Steininger, P. et al. Fatal Puumala Hantavirus Infection in a Patient with Common Variable Immunodeficiency (CVID). Microorganisms 11, 283 (2023).","journal-title":"Microorganisms"},{"key":"201_CR10","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2009040","volume":"383","author":"VP Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez, V. P. et al. Super-Spreaders\u201d and person-to-person transmission of Andes Virus in Argentina. N. Engl. J. Med. 383, 2230\u20132241 (2020).","journal-title":"N. Engl. J. Med."},{"key":"201_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/viro.1997.8976","volume":"241","author":"PJ Padula","year":"1998","unstructured":"Padula, P. J. et al. Hantavirus pulmonary Syndrome Outbreak in Argentina: molecular evidence for person-to-person transmission of Andes Virus. Virology 241, 323\u2013330 (1998).","journal-title":"Virology"},{"key":"201_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3201\/eid2604.190799","volume":"26","author":"DO Alonso","year":"2020","unstructured":"Alonso, D. O. et al. Person-to-person transmission of Andes Virus in Hantavirus Pulmonary Syndrome, Argentina, 2014. Emerg. Infect. Dis. 26, 756\u2013759 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"201_CR13","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.3390\/v15112266","volume":"15","author":"R Z\u00fcst","year":"2023","unstructured":"Z\u00fcst, R. et al. Presence and persistence of Andes virus RNA in human semen. Viruses 15, 2266 (2023).","journal-title":"Viruses"},{"key":"201_CR14","unstructured":"WHO. Hantavirus cluster linked to cruise ship travel, Multi-country; https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON601."},{"key":"201_CR15","unstructured":"Statement from the International Hantavirus Society and members of the international hantavirus research and clinical community regarding the current Andes virus outbreak investigation; https:\/\/zenodo.org\/records\/20298312."},{"key":"201_CR16","doi-asserted-by":"publisher","unstructured":"Andes Virus Outbreak Working Group. Andes Hantavirus Outbreak on a Cruise Ship, 2026. N. Engl. J. Med. NEJMc2606496. https:\/\/doi.org\/10.1056\/NEJMc2606496. (2026).","DOI":"10.1056\/NEJMc2606496"},{"key":"201_CR17","unstructured":"Complete sequence of Orthohantavirus andesense virus: Swiss resident. https:\/\/virological.org\/t\/complete-sequence-of-orthohantavirus-andesense-virus-swiss-resident-2026\/1023. (2026)."},{"key":"201_CR18","unstructured":"Pathoplexus ANDV sequences; https:\/\/pathoplexus.org\/andv\/search."},{"key":"201_CR19","unstructured":"Preliminary analysis of Orthohantavirus andesense virus sequences from a cruise-ship related cluster, May 2026; https:\/\/virological.org\/t\/preliminary-analysis-of-orthohantavirus-andesense-virus-sequences-from-a-cruise-ship-related-cluster-may-2026\/1029."},{"key":"201_CR20","doi-asserted-by":"publisher","first-page":"e0006901","DOI":"10.1371\/journal.pntd.0006901","volume":"13","author":"H Tian","year":"2019","unstructured":"Tian, H. & Stenseth, N. Chr. The ecological dynamics of hantavirus diseases: From environmental variability to disease prevention largely based on data from China. PLoS Negl. Trop. Dis. 13, e0006901 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"201_CR21","doi-asserted-by":"publisher","first-page":"1575112","DOI":"10.3389\/fimmu.2025.1575112","volume":"16","author":"A Tscherne","year":"2025","unstructured":"Tscherne, A., Guardado-Calvo, P., Clark, J. J., Krause, R. & Krammer, F. Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology. Front. Immunol. 16, 1575112 (2025).","journal-title":"Front. Immunol."},{"key":"201_CR22","first-page":"155","volume":"73","author":"M Goeijenbier","year":"2015","unstructured":"Goeijenbier, M. et al. Seoul hantavirus in brown rats in the Netherlands: implications for physicians-Epidemiology, clinical aspects, treatment and diagnostics. Neth. J. Med. 73, 155\u2013160 (2015).","journal-title":"Neth. J. Med."},{"key":"201_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1128\/CMR.00062-09","volume":"23","author":"CB Jonsson","year":"2010","unstructured":"Jonsson, C. B., Figueiredo, L. T. M. & Vapalahti, O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23, 412\u2013441 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"201_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/infdis\/146.5.638","volume":"146","author":"HW Lee","year":"1982","unstructured":"Lee, H. W., Baek, L. J. & Johnson, K. M. Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats. J. Infect. Dis. 146, 638\u2013644 (1982).","journal-title":"J. Infect. Dis."},{"key":"201_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3947\/ic.2021.0148","volume":"54","author":"M Tariq","year":"2022","unstructured":"Tariq, M. & Kim, D.-M. Hemorrhagic fever with renal syndrome: literature review, epidemiology, clinical picture and pathogenesis. Infect. Chemother. 54, 1 (2022).","journal-title":"Infect. Chemother."},{"key":"201_CR26","first-page":"793257","volume":"2015","author":"JW Golden","year":"2015","unstructured":"Golden, J. W., Hammerbeck, C. D., Mucker, E. M. & Brocato, R. L. Animal models for the study of rodent-borne hemorrhagic fever viruses: Arenaviruses and Hantaviruses. Biomed. Res. Int. 2015, 793257 (2015).","journal-title":"Biomed. Res. Int."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00201-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:03:35Z","timestamp":1780988615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00201-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00201-9","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics, which list FK as a co-inventor, and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. FK is co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus, and Pfizer, and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with Sanofi on SARS-CoV-2 variant monitoring.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}